Table 1.

Summary of the animals used for the study and the experimental design of the ZDF study [11,12,13]. In total, 18 ZDF rats and 5 wild-type rats, at the age of 11 weeks, underwent femur subcritical defect surgery. After 24 h, ZDF rats were randomized into a placebo treatment with vehicle solution (placebo, n = 5), PTH treatment (PTH, n = 5), insulin treatment (n = 4), or anti-sclerostin treatment (anti-scl, n = 5) for 12 weeks. Micro-CT, serum, and tissue analyses were performed as indicated in the Materials and Methods Section.

Genotype	Type of Treatment	Age at Beginning of Study	Treatment Administration	Treatment Duration	No. of Animals	Bone Defect	Serum/Ulna Collection at 12 Weeks	Original Reference
WT	Placebo	11 weeks	s.c. (daily)	12 weeks	5	yes	yes/yes	[12,13]
ZDF	Placebo	11 weeks	s.c. (daily)	12 weeks	5	yes	yes/yes	[12,13]
WT	Anti-Sclerostin	11 weeks	s.c. (twice a week) 25 mg/kg	12 weeks	4	yes	yes/no	[11]
ZDF	Anti-Sclerostin	11 weeks	s.c. (twice a week) 25 mg/kg	12 weeks	4	yes	yes/no	[11]
WT	PTH	11 weeks	s.c. (5 times a week) 75 µg/kg	12 weeks	5	yes	yes/yes	[12]
ZDF	PTH	11 weeks	s.c. (5 times a week) 75 µg/kg	12 weeks	5	yes	yes/yes	[12]
ZDF	Insulin	11 weeks	s.c. (daily) 0.5 IU at week 1–13 IU at week 12	12 weeks	4	yes	yes/no	[13]